Photoinduced Electron-Transfer Reactions of Carbonic Anhydrase Inhibitor Containing Tris(2,2′-bipyridine)ruthenium(II) Analogue

Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

While medicinal inorganic chemistry has been practised for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chemistry that we began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes. We can now readily manipulate and fine-tune their properties. This had led to a multitude of complexes with wide-ranging biomedical applications. This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer. With major advances in technologies and a deeper understanding of the human genome, we are now in a strong position to more fully understand carcinogenesis at a molecular level. We can now also rationally design and develop drug molecules that can either selectively enhance or disrupt key biological processes and, in doing so, optimize their therapeutic potential. This has heralded a new era in drug design in which we are moving from a single- toward a multitargeted approach. This approach lies at the very heart of medicinal inorganic chemistry. In this review, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens. We have focused our attention on metallodrugs incorporating platinum and ruthenium ions given that complexes containing these metal ions are already in clinical use or have advanced to clinical trials as anticancer agents. The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins. Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described. A summary of advances in this field over the past decade or so will be provided.

Study of the redox properties of singlet and triplet Tris(2,2'-bipyridine)ruthenium(II) ([Ru(bpy)3]2+) in aqueous solution by full quantum and mixed quantum/classical molecular dynamics simulations

The oxidation of ground-state (singlet) and triplet [Ru(bpy)3](2+) were studied by full quantum-mechanical (QM) and mixed quantum/classical (QM/MM) molecular dynamics simulations. Both approaches provide reliable results for the redox potentials of the two spin states. The two redox reactions closely obey Marcus theory for electron transfer. The free energy difference between the two [Ru(bpy)3](2+) states amounts to 1.78 eV from both QM and QM/MM simulations. The two methods also provide similar results for the reorganization free energy associated with the transition from singlet to triplet [Ru(bpy)3](2+) (0.06 eV for QM and 0.07 eV for QM/MM). On the basis of single-point calculations, we estimate the entropic contribution to the free energy difference between singlet and triplet [Ru(bpy)3](2+) to be 0.27 eV, which is significantly greater than previously assumed (0.03 eV) and in contradiction with the assumption that the transition between these two states can be accurately described using purely energetic considerations. Employing a thermodynamic cycle involving singlet [Ru(bpy)3](2+), triplet [Ru(bpy)3](2+), and [Ru(bpy)3](3+), we calculated the triplet oxidation potential to be -0.62 V vs the standard hydrogen electrode, which is significantly different from a previous experimental estimate based on energetic considerations only (-0.86 V).